Well I have a headache trying to work out these results. The previous year comparisons are misleading given they mix up NST only and NST/SAR. Not happy shareholder with this type of reporting. Combined group underlying profit is down. Last year NPAT (underlying) was $501M (291 NST +211 SAR) not $291M. For the production figures they conveniently used the combined group.
Underlying NPAT is not an increase. It is a decrease of 42% not an increase of 28%. The presentation is misleading and an insult to the intelligence of investors.
NST do better!!
- Forums
- ASX - By Stock
- NST
- Ann: FY21 Financial Results Presentation
Ann: FY21 Financial Results Presentation, page-19
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
RCE
Phase II clinical trial recruitment for R327G topical gel passes halfway, showing promising results against bacterial skin infections
LU7
The Breakdown: Lithium Universe talks refinery design and lithium processing in strong preliminary feasibility study for Bécancour
Add NST (ASX) to my watchlist
(20min delay)
|
|||||
Last
$15.79 |
Change
0.000(0.00%) |
Mkt cap ! $18.15B |
Open | High | Low | Value | Volume |
0.0¢ | $15.98 | $15.71 | $832.5K | 52K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 823 | $16.72 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.01 | 5585 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 823 | 16.720 |
2 | 1036 | 16.690 |
4 | 148 | 16.660 |
1 | 985 | 16.580 |
7 | 2483 | 16.570 |
Price($) | Vol. | No. |
---|---|---|
15.010 | 5585 | 2 |
15.350 | 73 | 1 |
15.370 | 16 | 3 |
15.400 | 935 | 3 |
15.450 | 6392 | 2 |
Last trade - 10.00am 11/10/2024 (20 minute delay) ? |
Featured News
NST (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online